Compound News and Research

RSS

CytRx to present new data on molecular chaperone drug discovery technology

CytRx Corporation today announced that Bin Zhang, Ph.D., Associate Director of Biochemistry and Screening, will present at the monthly meeting of the San Diego "LEADS" discussion group, the premium San Diego consortium of screening researchers, to be held on October 1, 2008.

25 Sep 2008

New tool for 'right first time' drug manufacture

A technology which provides high quality images of the crystallisation process marks the next step towards a 'right first time' approach to drug manufacture, according to engineers at the University of Leeds.

From Malvern Panalytical 23 Sep 2008

Almost 13,000 Chinese babies now sick from contaminated milk

China's Health Ministry says almost 13,000 babies have been taken to hospital suffering from the effects of drinking milk contaminated with the chemical melamine - most 2 years old or younger and four children have already died.

22 Sep 2008

Researchers turn plant cells into medical factories

VTT Technical Research Centre of Finland will coordinate the large EU research project called SmartCell. The four-year project focuses on developing methods for production of valuable pharmaceutical compounds using plant cells as a production host in an effective and controlled manner.

21 Sep 2008

Arana updates inflammatory pipeline milestones

Biotechnology company Arana Therapeutics Limited today provided an update on the major inflammatory compounds in its drug development pipeline. As part of this update, Arana said it has developed a new antibody candidate ART123, targeting inflammatory diseases and it plans to start a Phase I clinical trial for age-related macular degeneration (AMD) candidate PMX53 in 2009.

21 Sep 2008

A blood marker may indicate Alzheimer's risk

A simple blood test capable of predicting if a person might develop Alzheimer's disease is within sight, and could eventually be used to help scientists reverse onset of the disease in those most at risk.

17 Sep 2008

GlaxoSmithKline and XenoPort submit NDA for Solzira for restless legs syndrome

GlaxoSmithKline and XenoPort, Inc. announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

16 Sep 2008

NAMPA statement regarding JAMA study on bisphenol A

As with any new research regarding potential health effects associated with bisphenol A (BPA), the North American Metal Packaging Alliance, Inc. (NAMPA) takes seriously the findings of this latest study published in the Journal of the American Medical Association (JAMA).

16 Sep 2008

New drug might make tumor cells more sensitive to therapy

Scientists at St. Jude Children's Research Hospital have shown that it might be possible to make tumor cells more sensitive to irradiation and some types of chemotherapy by treating them with a drug that cripples their ability to repair DNA damage caused by these therapies.

16 Sep 2008

Trabectedin shows promise for ovarian cancer

Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.

15 Sep 2008

Promising new treatment option for women with recurrent ovarian cancer

Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

15 Sep 2008

Herpes drug Acyclovir could help control HIV

Acyclovir -- a low-cost, generic drug used to treat herpes -- also might help control HIV in people living with both viruses, according to a study published Wednesday in the journal ell Host and Microbe, Reuters reports.

15 Sep 2008

Scientists discover how to isolate cancer stem cells in tumors

After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning.

11 Sep 2008

Newly discovered molecule promises better treatments for heart attacks, heart surgery

Scientists have discovered a compound that could lead to new treatments for heart attacks as well as methods to protect hearts during open heart surgery and other situations in which blood flow to the heart is interrupted.

11 Sep 2008

Naltrexone-derived pyridomorphinan shows promise for treatment of alcoholism

Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry.

11 Sep 2008

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

The drug acyclovir has long been used to suppress outbreaks of oral and genital herpes. Herpes viruses change acyclovir to a form that prevents them from reproducing.

10 Sep 2008

New nanotechnology paints for hospitals could kill superbugs

New nanotechnology paints for walls, ceilings, and surfaces could be used to kill hospital superbugs when fluorescent lights are switched on, scientists heard today (Wednesday 10 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

9 Sep 2008

Bacteria's sticky glue is clue to vaccine says scientist

Sticky glue secreted by the bacterium Staphylococcus aureus could be the clue scientists have been searching for to make an effective vaccine against MRSA, medical researchers heard today (Wednesday 10 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

9 Sep 2008

Orexo and Boehringer Ingelheim extend collaboration

Orexo AB, the Swedish pharmaceutical company and Boehringer Ingelheim, the international pharmaceutical company headquartered in Ingelheim, Germany, have extended their existing three year research collaboration for a further 12 months from November 2008.

8 Sep 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008